Featuring perspectives from Dr Jeremy S Abramson and Dr Manali Kamdar, including the following topics: Introduction: About This Program (0:00) Overview of Chimeric Antigen Receptor (CAR) T-Cell Therapy (3:10) Potential Treatment Benefits of CAR T-Cell Therapy (10:35) CRS (Cytokine Release Syndrome) and ICANS (Immune Effector Cell-Associated Neuroto…

Featuring slide presentations and related discussion from Prof Francois-Clement Bidard, Dr Hope S Rugo, Dr Rebecca Shatsky and Dr Seth Wander, including the following topics: Optimal approach to biomarker testing for patients with ER-positive metastatic breast cancer (mBC) (0:00) Case: A woman in her early 70s with recurrent ER-positive, HER2-negat…

Featuring perspectives from Dr Matthew Lunning and Dr Sonali M Smith, including the following topics: Which Driver and Which Race: CAR-T and Bispecific Antibodies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma — Dr Lunning (0:00) Available and Emerging Novel Therapies for Diffuse Large B-Cell Lymphoma and Follicula…

Featuring perspectives from Dr Emmanuel S Antonarakis and Dr Matthew R Smith, including the following topics: Current and Future Role of Immune Checkpoint Inhibitors in the Management of Colorectal Cancer — Dr Lieu (0:00) Other Biomarker-Based Strategies for Patients with Colorectal Cancer — Dr Strickler (36:39) CE information and select publicatio…

Featuring perspectives from Dr Emmanuel S Antonarakis and Dr Matthew R Smith, including the following topics: Introduction (0:00) Optimizing the Role of Hormonal Therapy in the Care of Patients with Prostate Cancer — Dr Smith (0:55) Available and Emerging Therapeutic Approaches for Metastatic Castration-Resistant Prostate Cancer — Dr Antonarakis (2…

Featuring perspectives from Dr Harold J Burstein, Dr Matthew P Goetz, Dr Heather McArthur and Dr Rita Nanda, including the following topics: Introduction (0:00) Localized Hormone Receptor (HR)-Positive Breast Cancer; Initial Therapy for Metastatic Disease — Dr Goetz (4:48) Relapsed/Refractory HR-Positive Metastatic Breast Cancer — Dr Nanda (29:45) …

Featuring an interview with Dr Aaron Lisberg, including the following topics: Prevention and Management of Adverse Events of Special Interest with Datopotamab Deruxtecan (Dato-DXd) (0:00) Rugo H et al. US expert Delphi consensus on the prevention and management of stomatitis in patients treated with datopotamab deruxtecan. Support Care Cancer 2025;…

Featuring perspectives from Dr Kathleen N Moore and Dr Matthew A Powell, including the following topics: Introduction: A Pan-tumor Perspective on Microsatellite Instability (MSI)-High Disease — Immunotherapy for Localized Disease (0:00) Case: A woman in her early 60s with mismatch repair-deficient metastatic endometrial cancer (EC) and multiple pos…

Featuring an interview with Prof Patrick Neven, including the following topics: Emergence of ESR1 mutations in ER-positive, HER2-negative breast cancer (0:00) Observed toxicity profile of oral selective estrogen receptor degraders (SERDs) (3:57) Emerging data with novel oral SERD combinations (6:31) Challenges for a general medical oncologist in br…

Featuring a slide presentation and related discussion from Prof Patrick Neven, including the following topics: Biology of the estrogen receptor (ER) and mechanisms of resistance to therapy (0:00) Clinical trial data involving oral selective ER degraders (SERDs) for endocrine-resistant ER-positive, HER2-negative metastatic breast cancer (13:34) Util…

Featuring an interview from Dr John Strickler, including the following topics: Prognostic value of molecular residual disease (MRD) as detected by circulating tumor DNA (ctDNA) and optimal incorporation of MRD assays into the care of patients with colorectal cancer (0:00) Potential use of MRD assays for patients with microsatellite instability (MSI…

Featuring a slide presentation and related discussion from Dr John Strickler, including the following topics: Defining molecular residual disease (MRD); tumor-informed and tumor-naïve methods for assessing (0:00) GALAXY and BESPOKE CRC studies of a tumor-informed MRD assay to identify patients with localized colorectal cancer who have an increased …

Featuring an interview with Dr Kevin Kalinsky, including the following topics: Prophylaxis, Monitoring and Management of Adverse Events of Special Interest with Datopotamab Deruxtecan (0:00) Lisberg A et al. Datopotamab deruxtecan-associated select adverse events: Clinical practices and institutional protocols on prophylaxis, monitoring, and manage…